Özgür Deniz TURAN, Nesibe KAHRAMAN ÇETİN

Endometrial Kanser Evresi, Hastalığın Biyokimyasal Belirteçleri ve Vücut Kitle İndeksi Arasındaki İlişki

GİRİŞ ve AMAÇ: Literatürde obezitenin endometriyal kanserevresi ve biyolojik davranış üzerindeki etkileri üzerine yapılanaz sayıdaki çalışma sonuçları çelişkilidir. Bu nedenleçalışmamızda endometriyal kanserli hastalarda vücut kütleendeksi ile hastalık evresi ve hastalığın moleküler belirteçleriarasındaki ilişkinin araştırılması amaçlanmıştır. YÖNTEM ve GEREÇLER: Kliniğimizde opere edilenendometriyal kanser tanılı olgularının arşiv kayıtları vepatolojik raporları retrospektif olarak incelendi. Kliniğimizdeopere edilen endometriyal kanser tanılı olgularının arşivkayıtları (patoloji ve klinik raporları) retrospektif olarakincelendi. Olguların vücut kütle endeksi değerleri dünya sağlıkörgütü kriterlerine göre üç gruba ayrıldı. Sonrasında,grupların demografik, klinik, patolojik özellikleri ve molekülerbelirteçleri (Östrojen reseptörleri, progesteron reseptörleri veP53) karşılaştırıldı. BULGULAR: Çalışmaya toplam 99 vaka dahil edildi. Gruplararasında menapoz varlığı (p=0.042) ve hipertansiyon dışındakidemografik verilerde (p =0.038) anlamlı fark yoktu.Endometriyal kansere ait klinik karakteristiklerkarşılaştırıldığında ise tümör çapının (p=0.026) ve kansertipinin (p=0.042) gruplar arasında istatisitiksel olarak anlamlışekilde farklı olduğu gözlendi. Vücut kütle endeksinin en fazlaolduğu grupta (≥35kg/m2) endometriyal kanserin nonendometrioid alt tipi en yüksek oranda izlendi. Hastalık evresive hastalığa ait moleküler belirteçler ile gruplar arasındaanlamlı bir ilişki bulunmadı (p>0.05). TARTIŞMA ve SONUÇ: Endometriyal kanser hastaları içindeikinci ve üçüncü derece obesitesi bulunan grupta, daha agresivdavranış gösteren non endometrioid tip tümör görülme riskiartıyor görünmektedir. Ancak vücut kütle endeksi ile hastalıkevresi ve hastalığa ait diğer markırlar arasında ilişkibulunamamıştır.

The Association Between Endometrial Cancer Stage, BiochemicalMarkers of The Disease and Body Mass Index

INTRODUCTION: The results of the few studies in literatureon the effects of obesity on stage and biological behavior of theendometrial cancer are conflicting. Therefore, it was aimed toinvestigate the relationship between body mass index (BMI)and disease stage and molecular markers of the disease inpatients with endometrial cancer in our study. METHODS: Archive records (pathological and clinical reports) of patients diagnosed with endometrial cancer whowere operated in our clinic were analyzed retrospectively. TheBMI values of the cases were divided into three groupsaccording to the criteria of the world health organization.Then, the demographic, clinical, pathological characteristicsand molecular markers (estrogen receptors, progesteronereceptors and P53) of the groups were compared. RESULTS: A total of 99 cases were included in the study.There was no significant difference in demographic data(p=0.038) except for hypertension and the presence ofmenopause (p=0.042) between the groups. Among the clinicalfeatures, tumor diameter (p = 0.026) and cancer type (p =0.042) were found to be statistically significant between thegroups. In the group with the highest BMI (>35 kg/m2), thenon-endometrioid subtype of endometrial cancer was observedwith the highest rate. There was no significant relationshipbetween stage and molecular markers of the disease with thegroups (p>0.05). DISCUSSION AND CONCLUSION: Endometrial cancerpatients with second and third degree obesity seem to have anincreased risk of endometrioid type tumors with moreaggressive behavior, but there was no relationship betweenstage and other markers of the disease with BMI.

PDF

___

1. Suri V, Arora A. Management of endometrial cancer: a review. Rev Recent Clin Trials. 2015; 10(4): 309-16.
2. Wynder EL, Escher GC, Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer. 1966; 19: 489–520.
3. Suarez AA, Felix AS, Cohn DE. Bokhman Redux: Endometrial cancer “types” in the 21st century. Gynecol Oncol. 2017; 144: 243–9.
4. Michaela A Onstad, Rosemarie E, Schmandt, Karen H Lu. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. Obstet Gynecol. J Clin Oncol. 2016; 34(35): 4225– 4230.
5. Everett E, Tamimi H, Greer B, E Swisher, P Paley, L Mandel, et al. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patientswith endometrial cancer. Gynecol Oncol. 2003; 90: 150–7.
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 1625–38.
7. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894:i-xii, 1-253.
8. Katherine M Flegal 1, Brian K Kit, Heather Orpana, Barry I Graubard. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013; 309(1): 71-82.
9. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009; 105: 109.
10. Pavelka JC, Ben-Shachar I, Fowler JM, Ramirez NC, Copeland LJ, Eaton LA, et al. Morbid obesity and endometrial cancer: surgical, clinical, and pathologic outcomes in surgically managed patients. Gynecol Oncol. 2004; 95: 588-92.
11. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011; 377(9765): 557-67.
12. Arem H, Irwin ML. Obesity and endometrial cancer survival: a systematic review. Int J Obes (Lond). 2013; 37: 634-9.
13. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. 2002; 11(12): 1531–1543.
14. Bjorge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, et al., Metabolic syndrome and endometrial carcinoma, Am J Epidemiol. 2010; 171(8): 892–902.
15. Chia VM, Newcomb PA, Trentham-Dietz A, Hampton JM, Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis, Int J Gynecol Cancer. 2007; 17(2): 441– 446.
16. Jeon YT, Park IA, Kim YB, JW, Park NH, Kang SB, et al. Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett. 2006; 239(2): 198‐204.
17. Shen F, Gao Y, Ding J, Chen Q. Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer? Oncotarget. 2017; 8(1): 506-511.
18. Stelloo E, Nout RA, Osse EM, JürgenliemkSchulz IJ, Jobsen JJ, Lutgens LC, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early stage endometrial cancer, combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016; 22(16): 4215-4224.
19. Markova I, Duskova M, Lubusky M, Kudela M, Zapletalová J, Procházka M, et al. Selected immunohistochemical prognostic factors in endometrial cancer. Int J Gynecol Cancer. 2010; 20(4): 576‐582.
20. Tomica D, Ramić S, Danolić D, Šušnjar L, Perić‐Balja M, Puljiz M. Impact of estrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer. J Obstet Gynaecol. 2018; 38(1): 96‐102.
21. Busch EL, Crous-Bou M, Prescott J, Chen MM, Downing MJ, Rosner BA, et al. Endometrial cancer risk factors, hormone receptors, and mortality prediction. American Association for Cancer Research. 2017; 26(5): 727-735. DOI: 10.1158/1055-9965.EPI-16-0821.
22. Mauland KK, Trovik J, Wik E, Raeder MB, Njølstad TS, Stefansson IM et al. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. Br J Cancer. 2011; 104(6): 921–6.
23. Reeves KW, Carter GC, Rodabough RJ, Lane D, McNeeley SG, Stefanick ML, et al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative. Gynecol Oncol. 2011; 121(2): 376–82.
24. Sollberger TL, Gavrilyuk O, Rylander C. Excess body weight and ıncidence of type 1 and type 2 endometrial cancer: the Norwegian women and cancer study. Clinical Epidemiology. 2020; 12: 815–824.
25. Foley K, Lee RB. Surgical complications of obese patients with endometrial carcinoma. Gynecol Oncol. 1990; 39: 171-4.
26. Villareal DT, Apovian CM, Kushner RF, Klein S. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr. 2005; 82: 923-34.
27. Abu-Rustum NR, Zhou Q, Gomez JD, K M Alektiar, M L Hensley, R A Soslow, et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol. 2010; 116(3): 399.